Whats new
Whats new.
CLSA Equity Research - Hitchin’ a ride - BMS’ LAG-3 FDA approval could see increased interest in I-O sector (ASX:IMM) (Analyst: Andrew Paine)
March 1st 2022
For a copy of this research report please contact your CLSA advisor.
Whats new
March 1st 2022
For a copy of this research report please contact your CLSA advisor.